Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01935713 · ClinicalTrials.gov registry record · NA

Preliminary Investigation of Novel Methods to Reduce Children's Secondhand Smoke Exposure

A NA study, sponsored by University of Oklahoma.

Completed
Registry status
NA
Development phase
89
Enrollment target

NCT01935713: Completed NA study, sponsored by University of Oklahoma.

NCT01935713 is a NA study that has completed, run by University of Oklahoma. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01935713, a NA study, has completed, sponsored by University of Oklahoma.

COMPLETED
Registry status
NA
Development phase
89 participants
Enrollment target

Study Summary

The overall aim of the current study is to determine if the use of nicotine containing products by caregivers who smoke and who are not interested in quitting, is effective in reducing children's secondhand smoke exposure.

Primary Outcome

Child salivary cotinine will be measured to assess the level of secondhand smoke exposure. We will measure the change throughout the study.

Interventions

  • DRUG Electronic Cigarette
  • DRUG Nicotine polacrilex
  • DRUG Dissolvable Tobacco Lozenge

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2012-04
Est. Completion 2012-12
Phase NA
University of Oklahoma

358 total trials

What the finished NCT01935713 record still lists

NCT01935713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 3 interventions - of which Electronic Cigarette is the first listed.

NCT01935713 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01935713 about?

NCT01935713 is a clinical study titled "Preliminary Investigation of Novel Methods to Reduce Children's Secondhand Smoke Exposure". The overall aim of the current study is to determine if the use of nicotine containing products by caregivers who smoke and who are not interested in quitting, is effective in reducing children's secondhand smoke exposure.

What is the current status of trial NCT01935713?

This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2012-04. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01935713?

The interventions under investigation include: Electronic Cigarette (DRUG), Nicotine polacrilex (DRUG), Dissolvable Tobacco Lozenge (DRUG).

Who is sponsoring clinical trial NCT01935713?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01935713's enrollment target sits among peer trials

89 972nd of 2000 higher than 1,029 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03682289 · 89 participants · Phase 2

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

  • NCT04787939 · 89 participants · NA

    Early Feeding After Oral Cavity Reconstruction

  • NCT05480449 · 89 participants · Phase 1

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • NCT05604131 · 89 participants · Phase 2

    Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01935713, the US trial registry maintained by the National Library of Medicine. NCT01935713 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.